Summary by Moomoo AI
Kaiji Pharmaceutical-B (02171.HK) submitted the disclosure report for the next day on June 13, 2024, disclosing the changes in the issued shares or inventory shares. The report shows that the company has conducted multiple share buybacks between May 31, 2024 and June 13, 2024, with a total buyback of 1,503,000 shares, accounting for 0.261% of the issued shares. The latest buyback occurred on June 13, 2024, with a buyback of 5,000 shares at a buyback price of HKD 5.74 per share, for a total amount of HKD 28,700. The shares will be intended for cancellation. The company confirms that all share buybacks have been approved by the board of directors and comply with relevant listing rules and legal requirements. In addition, the company will comply with the relevant regulations' suspension period after share buybacks until July 13, 2024.